Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Federal data show health disparities among states
12 Dec 2013 at 12:34am
JEFFERSON CITY, Mo. (AP) ? The slow rollout of a new federal health insurance marketplace may be deepening differences in health coverage among Americans, with residents in some states gaining insurance at a far greater rate than others.
Studies: Some cancer treatments can be skipped
11 Dec 2013 at 11:28am
SAN ANTONIO (AP) ? Tens of thousands of women each year might be able to skip at least some of the grueling treatments for breast cancer ? which can include surgery, heavy chemo and radiation ? without greatly harming their odds of survival, new research suggests.
Fight against malaria slows, fewer nets given out
11 Dec 2013 at 8:03am
LONDON (AP) ? Global efforts to curb malaria are stalling after a drop in funds to buy bed nets, according to the latest report Wednesday from the World Health Organization.
Signer says suffered schizophrenic episode at Mandela memorial
12 Dec 2013 at 3:09am
By Olivia Kumwenda-Mtambo JOHANNESBURG (Reuters) - A South African sign language interpreter accused of miming nonsense as world leaders paid tribute to Nelson Mandela defended himself as a "champion" signer on Thursday, but said he suffered a schizophrenic episode during the event. The interpreter, 34-year-old Thamsanqa Jantjie, told Johannesburg's Star newspaper he started hearing voices and hallucinating while on stage, resulting in gestures that made no sense to outraged deaf people around the world. Millions of TV viewers saw Jantjie interpreting for leaders including U.S. President Barack Obama and his South African counterpart, Jacob Zuma, at Tuesday's Mandela memorial. Afterwards South Africa's leading deaf association denounced Jantjie as a fake who was making up gestures as he stood yards away from world leaders.
Pope attacks mega-salaries, big bonuses, in peace message
12 Dec 2013 at 3:04am
By Philip Pullella VATICAN CITY (Reuters) - Pope Francis attacked mega-salaries and big bonuses on Thursday, saying in the first peace message of his pontificate that they are symptoms of an economy based on greed and inequality. In his message for the Roman Catholic Church's World Day of Peace, marked by the Church around the world on January 1, he also called for more sharing of wealth among people and nations to narrow the gap between the rich and poor. "The succession of economic crises should lead to a timely rethinking of our models of economic development and to a change in lifestyles," he said.
Indian ban on gay sex violates international law: U.N
12 Dec 2013 at 2:55am
A decision by the Indian Supreme Court to reinstate a ban on gay sex represents a "significant step backwards for India" and violates international law, United Nations human rights chief Navi Pillay said on Thursday, suggesting the case be reheard. In a major blow to gay rights in the world's largest democracy, the Supreme Court on Wednesday threw out a 2009 ruling by a lower court that had decriminalized gay sex. "Criminalizing private, consensual same-sex sexual conduct violates the rights to privacy and to non-discrimination enshrined in the International Covenant on Civil and Political Rights, which India has ratified," Pillay said in a statement issued in Geneva. "Yesterday's Supreme Court decision in this case represents a significant step backwards for India and a blow for human rights." The top court stated that only India's government could change the law, deeming the Delhi High Court had overstepped its powers with the decision four years ago.
Cancer deaths rise to 8.2 million, breast cancer sharply up
12 Dec 2013 at 2:52am
By Kate Kelland LONDON (Reuters) - The global death toll from cancer rose to 8.2 million in 2012 with sharp rises in breast cancer as the disease tightened its grip in developing nations struggling to treat an illness driven by Western lifestyles. Cancer deaths were up 8 percent from 7.6 million in a previous survey in 2008 and breast cancer killed 522,000 women last year, up 14 percent in the same period, according to the World Health Organisation's International Agency for Research on Cancer (IARC). "Breast cancer is also a leading cause of cancer death in the less developed countries of the world," said David Forman, head of IARC's Section of Cancer Information, the group that compiles the global cancer data.
Apple sends medical experts to Pegatron factory after worker death
12 Dec 2013 at 1:36am
Apple Inc on Thursday said it sent medical experts to contractor Pegatron Corp's Shanghai factory last month after a 15-year-old employee died of pneumonia. Apple has taken various measures in response to criticism that its products were made in sweatshop-like conditions, since employee suicides at supplier Foxconn in 2010. Last year, it commissioned the Fair Labor Association to investigate suppliers' factories. "Last month we sent independent medical experts from the U.S. and China to conduct an investigation at the factory," Apple said in a statement.
Bristol adds medicine to patent pool for AIDS drugs
12 Dec 2013 at 1:08am
Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries. The licensing deal will enable generic drug firms around the world to produce affordable versions of atazanavir, which Bristol sells under the brand name Reyataz, and to combine it with other medicines to make treatment easier. The agreement announced on Thursday by the United Nations-backed Medicines Patent Pool is the first covering an HIV drug designed for use after patients develop resistance to initial treatments.
How Technology Is Warping Your Memory
12 Dec 2013 at 1:05am
Take a moment to think about the last time you memorized someone's phone number. And when was the last time you were at a dinner party or having a conversation with friends, when you whipped out your smartphone to Google the answer to someone's question?
For some Obamacare shoppers, a brief grace period on premiums
11 Dec 2013 at 10:10pm
By Caroline Humer and Lewis Krauskopf NEW YORK (Reuters) - As a deadline approaches for people to sign up for medical insurance under President Barack Obama's healthcare law, some insurers and state-run online marketplaces are giving shoppers an extra week to pay their first premiums. The Obama administration could face a new crisis over the healthcare law should a significant number of consumers discover that their preferred insurer does not have a record of their new policy. Aetna Inc, which is selling health insurance on exchanges, or marketplaces, in more than a dozen states, will allow consumers to pay premiums as late as January 8. The Connecticut exchange, Access Health CT, said some shoppers can pay as late as January 7.
Insight: Philips restores profit by rediscovering relevance
11 Dec 2013 at 9:04pm
By Sara Webb AMSTERDAM (Reuters) - Every year Singaporeans and Malaysians choke on smoke when farmers and plantation firms in neighboring Indonesia clear the land with fires during the dry season. Last summer, Philips diverted stocks of air purifiers from Hong Kong and China to the area in time for the worst pollution in 16 years. The switch of supplies was emblematic of a more nimble approach fostered by Chief Executive Frans van Houten that has helped Philips reinvent itself in healthcare, lighting and consumer goods and revived the company's fortunes. ...
Budget deal headed to vote in U.S. House, passage predicted
11 Dec 2013 at 8:05pm
By David Lawder and Thomas Ferraro WASHINGTON (Reuters) - Republicans in the U.S. House of Representatives on Wednesday were falling in line behind a bipartisan two-year budget deal, indicating that the normally rambunctious group of lawmakers is not spoiling for a year-end fiscal fight. Despite conservative groups' denunciation of the plan and public opposition from some members associated with the conservative Tea Party movement, the Republican-controlled House was planning to vote on Thursday to pass the deal, Representative Kevin McCarthy, the third-ranking Republican told Reuters. A key House panel, on a 9-3 vote, cleared the legislation for debate and votes in the full House. The Republican-controlled Rules Committee refused to allow Democrats to offer an amendment to extend federal unemployment benefits that expire later this month.
China tells pilots to improve landing skills to deal with Beijing smog
11 Dec 2013 at 6:31pm
Chinese authorities have told pilots who fly to Beijing they must be qualified to land their aircraft in the low visibility bought about by smog, state media said on Thursday, as the government tries to reduce flight delays due to pollution. Beginning January 1, pilots flying from the country's 10 busiest airports into the Chinese capital must be qualified to use an instrument landing system on days when smog reduces visibility to around 400 meters (1,315 feet), the official China Daily said, citing China's civil aviation regulator. Despite investing billions of dollars in new airports and advanced Western-built aircraft, China suffers a chronic problem with flight delays, partly because of the country's often wildly-fluctuating weather and partly because the military tightly controls most of China's airspace.
California given two-month extension to reduce prison crowding
11 Dec 2013 at 6:19pm
By Sharon Bernstein SACRAMENTO, California (Reuters) - California will have an extra two months to reduce crowding in its prison system, a panel of three federal judges ruled on Wednesday, in the latest twist in a decades-long dispute over conditions and medical care for inmates. California prisons have been in the national spotlight for the past year as officials wrestled with crowding and concerns about the state's use of long-term solitary confinement for prisoners with suspected gang ties, which led to a hunger strike this year. The state has been under court orders to reduce inmate numbers since 2009, when the same panel ordered it to relieve overcrowding that several courts, including the U.S. Supreme Court, have said was to blame for inadequate medical and mental-health care. California Governor Jerry Brown has repeatedly said he believes that the state has fixed its problem.